Asset Details
Do you wish to reserve the book?
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis
Do you wish to request the book?
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis
2017
Overview
Ulcerative colitis (UC) is a relapsing-remitting chronic inflammatory disorder affecting the mucosal surface in a continuous manner from the rectum through part of, or the entire, colon. Patients with severe disease and those who become refractory or intolerant to corticosteroids and/or immunosuppressants, require treatment with biologic agents that target tumor necrosis factor-α (TNF). Golimumab, a fully human monoclonal antibody, is the latest TNF antagonist to get approved for the treatment of moderate-to-severe UC. Subcutaneously administered golimumab induces and maintains clinical response, remission, and mucosal healing. Serum concentrations of golimumab are associated with response to therapy, as patients with higher drug exposure are more likely to achieve these outcomes. Since various patient and disease-related factors were shown to influence the pharmacokinetics of TNF antagonists, drug exposure may be variable over time and between patients, affecting success of therapy. A major contributing factor is immunogenicity, with development of anti-drug antibodies (ADAb) and an accelerated clearance of drug as a result. Although there is a growing body of evidence to support therapeutic drug monitoring (TDM) for infliximab and adalimumab, two other TNF antagonists, only limited data is available for golimumab. In addition, the clinically important drug exposure thresholds are not widely known, which has limited the use of TDM for golimumab in clinical practice. This review summarizes available data regarding the use of golimumab for UC, with emphasis on the pharmacokinetics, exposure-response relationship, and the role of TDM in optimizing therapy.
Publisher
Springer US,Springer,Springer Nature B.V
Subject
/ Adalimumab - therapeutic use
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - immunology
/ Antibodies, Monoclonal - pharmacokinetics
/ Antibodies, Monoclonal - therapeutic use
/ Biomedical and Life Sciences
/ Biomedical Engineering and Bioengineering
/ Colitis, Ulcerative - drug therapy
/ Colon
/ Dose-Response Relationship, Drug
/ Humans
/ Infliximab - therapeutic use
/ Mucosa
/ Pharmacy
/ Rectum
/ Tumor Necrosis Factor-alpha - antagonists & inhibitors
